NEW YORK (GenomeWeb News) – ParagonDx said today that Iverson Genetic Diagnostics will use its pharmacogenomics test to determine warfarin sensitivity among patients taking the blood thinner.
 
IGD is a Seattle-based CLIA-certified lab that had been using a blood-based method for determining warfarin dosing, Research Triangle Park, NC-based ParagonDx said. Now, it will use a saliva-based test that incorporates ParagonDx’s technology and provides results the same day, as opposed to in two to three days with the blood-based test.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.